Dr. Mayo Friedlis - Stem Cell Therapy for Spine Problems
Dr. Mayo Friedlis of Stemcell ARTS (an affiliate of National Spine and Pain Centers) in Fairfax, Virginia introduces stem cell therapy, an innovative solution that can deliver non-surgical...
By: StemCell ARTS
Read the original here:
Dr. Mayo Friedlis - Stem Cell Therapy for Spine Problems - Video
Dr. Mayo Friedlis - Stem Cell Therapy for Hip Problems
Dr. Mayo Friedlis of Stemcell ARTS (an affiliate of National Spine and Pain Centers) in Fairfax, Virginia introduces stem cell therapy, an innovative solution that can deliver non-surgical...
By: StemCell ARTS
Read more here:
Dr. Mayo Friedlis - Stem Cell Therapy for Hip Problems - Video
Dr. Mayo Friedlis - When Should You Use Stem Cell Therapy?
Dr. Mayo Friedlis of Stemcell ARTS (an affiliate of National Spine and Pain Centers) in Fairfax, Virginia introduces stem cell therapy, an innovative solution that can deliver non-surgical...
By: StemCell ARTS
Read more:
Dr. Mayo Friedlis - When Should You Use Stem Cell Therapy? - Video
The bad news: "Stem cells by themselves do not work."
The good news: "Stem cells by themselves do not work."
Take it from the doctor who has treated 5,000 patients with stem cell therapy, a doctor who is himself a cancer survivor. Thirteen years ago, Dr. Sam Bernal - oncologist, chemist, molecular biologist, lawyer, professor and lecturer, among other things - was a cancer patient who thought he was at death's door. Using stem cells sourced from his bone marrow and peripheral blood, he overcame the disease and has since become an advocate of living fit, living well in order to look good.
Dr. Bernal, who divides his time between Los Angeles, Prague, Makati, and Germany, was a pioneer in stem cell research in the Philippines early on in his career, for which he was cited when he received the Presidential Award for Outstanding Filipinos Overseas from President Benigno S, Aquino III in 2012.
At a recent meeting with journalists, Dr. Bernal hurled the challenge: "What do you need stem cell therapy for if you eat well, sleep soundly, exercise regularly, don't smoke, have a positive attitude, and know how to live in the moment as you gaze at a painting and get a thrill out of small things like that?"
Not only is the doctor a passionate advocate of living the good life, the simple life, and, yes, Argentine tango - "It's better than boring exercises at the gym!" - he believes in healthy eating. "I brought a group of European friends to Manila and they were flabbergasted at our vegetable dishes - laing, gising-gising, buko juice - our simplest food was gourmet cuisine to them!"
No, he's not a vegetarian, but a "flexitarian."
But if stem cells - the body's own master and repair cells - aren't the key to staying young, what is? The holistic approach works best, according to the doctor, stating that the procedure should be recommended by doctors "on a case by case basis." In effect, the doctor prescribes "customizing your stem cell therapy."
In his book, molecular biology provides the battleground from which to attack the afflictions of aging that signal a desire or need to repair or replace one's stem cells. Speaking of books, Dr. Bernal continues to teach at Harvard, Ateneo, UST, and Medical City as a component of his mission to spread the benefits of technology transfer, which is the vision of his company, GlobeTek Science Foundation (based in Makati).
Read more:
‘Customize’ your stem cell therapy
2 months after stem cell therapy
Eveybody agrees that the therapy works. There is very big improvment the way Toby walks now.
By: Jacek Kozlowski
Original post:
2 months after stem cell therapy - Video
Bearded Collie OA BEFORE Stem Cell Therapy
By: MediVet Arizona
Read more from the original source:
Bearded Collie OA BEFORE Stem Cell Therapy - Video
By: Jet Villa, InterAksyon.com August 20, 2013 3:45 PM
InterAksyon.com The online news portal of TV5
MANILA, Philippines Reminder for those who wish to have their stem cell therapy practice and products accredited: You have until August 31 to register, the Department of Health said Tuesday.
Citing Administrative Order 2013-0012 issued March 18 this year, Health Secretary Enrique Ona said that while the Department of Health (DOH) supports scientific advancement in the field of cellular medicine, its priority is to protect the public from harm rather than give a blanket endorsement of its use or potential benefits.
Those who need to seek accreditation include: health care facilities doing stem cell therapy (with the DOH) as well as companies that import, market, and produce stem cell products (with the Food and Drug Administration, which is under DOH).
Ona said the DOH seeks to regulate stem cell therapy both as a recognized treatment modality and for research purposes.
"This is to allay fears that unscrupulous individuals or groups will engage in unethical practices and subject naive patients to undue harm and unproven medical claims," he added.
Among the DOH guidelines are:
Ona conceded that there are only a limited number of medical conditions in which stem cell therapy may be indicated.
Others are claims that should be taken with a grain of salt, he said.
Go here to see the original:
REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 - DOH
By Philip C. Tubeza Philippine Daily Inquirer
MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country.
Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org.
The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program.
Cease and desist
We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said.
The PCP, the umbrella organization of Internal Medicine specialists in the country, said that transplanting human blood-forming stem cells to treat cancerous and noncancerous diseases of the blood was the most widely accepted clinical application of stem cell therapy.
The effectiveness and safety of human stem cell therapy has yet to be proven for heart, neurologic, skin, rheumatologic and gastrointestinal diseases, diabetes, hypertension, autism, cancer, aging and aesthetics, HIV/AIDS and other conditions, the group said.
Lack of evidence
Despite the lack of solid scientific evidence to support the [application] of human stem cell therapy for these conditions, reports of its use precisely for these conditions being received and exorbitant fees being paid by prominent personalities abound in media, the PCP said.
See the original post:
Docs seek stop to expensive, experimental stem cell therapy
CHEYENNE, WY- (ACCESSWIRE - August 20,2013) - Therapy Cells Inc (OTC Pink: TCEL) announces that on 13 February 2013, US patent US 11/702,895 was awarded to renowned scientist Dr Patrick Casey and Transplantation Ltd, for his transformational cell therapy, exclusively licensed to Therapy Cells Inc for use in human applications.
This revolutionary science dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory. These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing.
The research team headed by Dr Casey has to date treated more than 80 horses including thoroughbreds, standardbreds, polo ponies and horses at the highest level of equestrian competition.
"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times." The horse is an FDA approved model species for athletic injuries.
Dr Casey is a Veterinary graduate from Massey University (BVSc, 1988), and graduate from the University of California in 1992 with a Doctor of Philosophy (PhD, Comparative Pathology). During his time in the United States he also completed an Equine Surgical Internship at Hagyard-Davidson and McGee, Lexington, Kentucky, followed by a three year residency programme in Equine Reproduction, with a minor in Equine Medicine at UC Davis. In 1992, 1993, and 1994 he received a post-doctoral fellowship from the Equine Research Laboratory at the University of California, which allowed him to set up with the late, world renowned, Professor Liggins at the University of Auckland, New Zealand.
Since 2011, Dr Casey has been chief scientific consultant to a public company in the USA - Therapy Cells Inc (TCEL on the OTC Market).
This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue, effectively by-passing the need for Stem Cell treatment.
"The financial and curative potential of this biotechnology platform is immediately obvious," states Dr Casey. "When we talk about regenerative procedures, the ability to rejuvenate tissues and organs with cultivated natural cell therapy, it's easy to understand how enormous the opportunity and the impact will be. The awarding of this US Patent for our transformational science is a significant milestone in the steps we have been taking to get our therapies to market."
Contact:
Contact: Patrick Casey
Read this article:
Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy
What #39;s Stem Cell Therapy Dr Bill Johnson Has Answers
for more information go to... http://www.innovationstemcellcenter.com More useful info below... Drapeau #39;s theory that Adult Stem Cells are nothing less than the hum...
By: Mark Khan
Read more from the original source:
What's Stem Cell Therapy Dr Bill Johnson Has Answers - Video
By: Jet Villa, InterAksyon.com August 18, 2013 5:02 PM
REUTERS FILE PHOTO
InterAksyon.com The online news portal of TV5
MANILA, Philippines - The Food and Drug Administration (FDA) will conduct on Friday, August 23, a public hearing on the regulation of stem cell therapy in the country.
The FDA said the public hearing is scheduled from 3 p.m. to 5 p,m, at the Audio-Visual Room, 3rd floor, Annex Building, FDA office on Civil Drive in Alabang Muntinlupa.
The purpose of the hearing is to discuss the regulation of stem cell therapy, the stem cell products, and the health facilities that are offering the service in the court, it said.
The FDA also established an online reporting system to document adverse events linked to human cells, tissues, and cellular- and tissue-based products such stem cell therapies acquired in any facility.
The agency said those who experienced any untoward event or side effect or treatment failures after undergoing stem cell procedures can report through FDA website at http://www.fda.gov.ph under eReport and Adverse Drug Reaction, Report section.
E-mails may also be sent toreport@fda.gov.ph.
All consumers are assuredthat all information given will be treated with utmost confidentiality.Contact details are needed in case of a need for follow-up and validation.However, anonymous reports will still be accepted, the FDA added.
Read more here:
FDA hearing on stem cell therapy set on Friday, Aug. 23
ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential use of embryonic mesenchymal progenitor cells, generated using BioTimes PureStemtechnology, in regenerative medicine and will contrast the properties of those cells with adult-derived mesenchymal stem cells. He will also discuss how those cells can be utilized in the search for genes potentially useful in induced tissue regeneration (iTR). The presentation will be available on BioTimes website at http://www.biotimeinc.com/scientific-presentations.
MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21, 2013, is being held at the Cleveland Marriott Downtown at Key Center and is presented by Case Western Reserve University and the National Center for Regenerative Medicine.
About BioTime, Inc
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:
Additional information about BioTime can be found on the web at http://www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.
Original post:
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine ...
Stem Cell Therapy Treatment for Peripheral Nerve Injury by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Peripheral Nerve Injury by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Dee...
By: Neurogen Brain and Spine Institute
Continued here:
Stem Cell Therapy Treatment for Peripheral Nerve Injury by Dr Alok Sharma, Mumbai, India. - Video
By: Jet Villa, InterAksyon.com August 16, 2013 8:24 AM
InterAksyon.com The online news portal of TV5
MANILA, Philippines -- (UPDATE - 10:12 a.m.) A consultant of Secretary Enrique Ona resigned Friday, calling the Health chiefs position that patients undergoing experimental stem cell therapy should pay unacceptable.
Dr. Anthony Leachon, who is in Davao City, said he emailed his resignation letter to Ona.
It is with deep regret that I'm resigning asDepartment of Health consultant for non-communicable diseases effective today (Friday). I have been privileged and honored to be a part of your administration even as a one peso a year consultant. I value our friendship and camaraderie which started years ago, Leachon, vice president of the Philippine College of Physicians and Onas consultant for non-communicable diseases, wrote.
Because his position is directly opposed to Onas, Leachon told the Health secretary, I believe I have lost your trust and confidence and I might not be effective serving the DOH and fighting the PCP and medical societies ' cause in the service of the Filipino patient.
Leachon was Onas consultant for non-communicable diseases since November 2011.
Ang pinaka-hindi ko nagustuhan ay yung sisingilin ang pasyente kahit clinical trial pa lang. Yon ang unacceptable sa akin (What I disagree with most is charging patients even if what they undergo are just clinical trials. That is unacceptable), Leachon said.
His resignation came as the National Health Institute, the research arm for health sciences of the University of the Philippines-Manila, joined the growing opposition to the Health secretarys stand on experimental stem cell therapy.
Leachon, a cardiologist at the Manila Doctors Hospital, called Onas position a complete violation of the Code of Ethics (for doctors) and being the secretary of health, alam niya dapat yon (he should know that). This is not a sign of ignorance, pero siguro may mga taong iba ang sinasabi sa kaniya (but there may be people telling him otherwise).
Continued here:
NIH joins opposition to charging patients for experimental stem cell therapy
By: Jet Villa, InterAksyon.com August 16, 2013 8:24 AM
InterAksyon.com The online news portal of TV5
MANILA, Philippines -- (UPDATE - 10:12 a.m.) A consultant of Secretary Enrique Ona resigned Friday, calling the Health chiefs position that patients undergoing experimental stem cell therapy should pay unacceptable.
Dr. Anthony Leachon, who is in Davao City, said he emailed his resignation letter to Ona.
It is with deep regret that I'm resigning asDepartment of Health consultant for non-communicable diseases effective today (Friday). I have been privileged and honored to be a part of your administration even as a one peso a year consultant. I value our friendship and camaraderie which started years ago, Leachon, vice president of the Philippine College of Physicians and Onas consultant for non-communicable diseases, wrote.
Because his position is directly opposed to Onas, Leachon told the Health secretary, I believe I have lost your trust and confidence and I might not be effective serving the DOH and fighting the PCP and medical societies ' cause in the service of the Filipino patient.
Leachon was Onas consultant for non-communicable diseases since November 2011.
Ang pinaka-hindi ko nagustuhan ay yung sisingilin ang pasyente kahit clinical trial pa lang. Yon ang unacceptable sa akin (What I disagree with most is charging patients even if what they undergo are just clinical trials. That is unacceptable), Leachon said.
His resignation came as the National Health Institute, the research arm for health sciences of the University of the Philippines-Manila, joined the growing opposition to the Health secretarys stand on experimental stem cell therapy.
Leachon, a cardiologist at the Manila Doctors Hospital, called Onas position a complete violation of the Code of Ethics (for doctors) and being the secretary of health, alam niya dapat yon (he should know that). This is not a sign of ignorance, pero siguro may mga taong iba ang sinasabi sa kaniya (but there may be people telling him otherwise).
See the article here:
Consultant quits over DOH chief's stand on stem cell therapy
Stem Cell Therapy Treatment for Congenital Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Congenital Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy ...
By: Neurogen Brain and Spine Institute
See the original post here:
Stem Cell Therapy Treatment for Congenital Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video
Poway, California (PRWEB) August 15, 2013
Robert J. Harman, DVM, Chief Executive Officer of Vet-Stem, Inc., a leading Regenerative Veterinary MedicineTM company located in San Diego, California, has been invited back to speak at the Adult Stem Cell Therapy and Regenerative Medicine Conference in Cleveland, Ohio August 19-21, 2013. The conference is presented by The National Center for the Regenerative Medicine (NCRM), Case Western Reserve University (CWRU), Cleveland Clinic (CC), and University Hospitals Case Medical Center (UHCMC) to bring together a global perspective on regenerative medicine and adult stem cell therapy.
Dr. Harman is scheduled as the first speaker of Session II titled Disease Models for Adult Stem Cell Therapy, and his presentation is One Medicine Natural Veterinary Disease Models.
He stands alone in his expertise in the field of Regenerative Veterinary Medicine among the 273 attendees from 100 institutions in 17 countries that make up the conference. Dr. Harman draws his knowledge from more than 10,000 horse, dog and cat patients treated over the last 10 years in both the U.S. and Canada using proprietary Vet-Stem technology.
Dr. Harman is sharing the podium with Case Western Reserve Universitys own Dr. Arnold Caplan, and revolutionary regenerative medicine companies such as BioTime, Terumo BCT, STROMALab, and Pfizer. Dr. Caplan, a technology pioneer in cell-based therapies in Regenerative Medicine, is a scientific advisor to Vet-Stem, Inc.
About Vet-Stem, Inc.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Read more from the original source:
Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Invited to Speak at the Adult Stem Cell Therapy and Regenerative ...
by Buena Bernal Posted on 08/15/2013 7:59 PM |Updated 08/15/2013 9:29 PM
PROBE STEM CELL THERAPY. Rep Paulino 'Doy' Leachon files a resolution to probe the conduct of stem cell therapy in the Philippines. Photo grabbed from islandsentinel.com
MANILA, Philippines - Rep Paulino Salvador "Doy" Leachon of Oriental Mindoro's 1st district filed on Thusday, August 15, a house resolution calling for a congressional inquiry in aid of legislation on the conduct of stem cell therapy in the country.
House Resolution 215 was filed a day after Leachon's scheduled privilege speech, calling for the resignation of Health Secretary Enrique Ona over the cabinet official's stand on stem cell therapy.
READ: Leachon asks Ona to resign over stem cell issue
The 40-year-old lawmaker also urged concerned government agencies to step up their regulatory oversight. These agencies include the Department of Health (DOH), the Food and Drug Administration (FDA), and the Professional Regulation Commission (PRC).
First attempt to regulate
Government regulation of stem cell treatment is still in its infancy stage, with the guidelines for accreditation of facilities released only in March.
It is DOH's first attempt at regulating the practice, despite the therapy having been administered by Filipino physicians for years now.
The types of stem cell treatment that are allowed, prohibited, and restricted (i.e. allowed but with limitations) in the facilities to be accredited by August 31 are listed in the released guidelines.
Go here to see the original:
Solon calls for probe into stem cell therapy
NewsLife: DOH calls for registration of stem cell therapy operators
NewsLife - DOH calls for registration of stem cell therapy operators (Reported By: Noel Perfecto) - [August 12, 2013] For more news, visit: #9659;http://www.ptvne...
By: PTV PH
View original post here:
NewsLife: DOH calls for registration of stem cell therapy operators - Video
By: Jet Villa, InterAksyon.com August 13, 2013 8:42 AM
InterAksyon.com The online news portal of TV5
MANILA, Philippines - The Department of Health (DOH) has given all health facilities practicing stem cell therapy and companies importing and producing stem cell products untilAug. 31to apply for accreditation and product registration, respectively.
Nick Lutero, director of the DOH-Bureau of Health Facilities and Services, said it will be considered illegal for facilities to do stem cell procedures if they fail to comply with the requirement.
Papatigil namin ang pag-conduct ng therapy. For those still continuing to practice, I think we have sufficient laws, particularly on the illegal practice of medicine. They could be criminally liable, he said in a chance interview.
Lutero lamented that only five hospitals have applied for registration although the DOH had issued the guidelines on this since March.
We have done preliminary visits sa mga hospitals na ito at mukang based sa initial inspection, merong sufficient compliance sa mga facilities, he said.
Companies importing and producing stem cell products, on the other hand, should apply for registration with the Food and Drug Administration, an agency attached to the DOH.
Products that will not be applied for registration will also be considered illegal after the deadline.
Experimental treatment not for free
More:
DOH gives health facilities engaged in stem cell therapy until Aug. 31 to register